High Grade Astrocytic Tumor
High grade astrocytic tumors most frequently harbor alterations in TP53, PTEN, CDKN2A, EGFR, and CDKN2B .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, CDKN2A Loss, and CDKN2B Loss are the most common alterations in high grade astrocytic tumor .
There is 1 clinical trial for high grade astrocytic tumor, of which 1 is open and 0 are completed or closed. Of the trial that contains high grade astrocytic tumor as an inclusion criterion, 1 is phase 1 (1 open).
Doxorubicin-loaded egfr-targeting nanocells is the most common intervention in high grade astrocytic tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.